Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
Epistemonikos ID: 811d197e8ee84fc36eb32c6e5e2e91acb22a70a2
First added on: Aug 17, 2021